These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. Steinhubl SR; Topol EJ J Thromb Thrombolysis; 1999 Jun; 7(3):227-31. PubMed ID: 10373712 [No Abstract] [Full Text] [Related]
5. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. Niessner A; Niessner H; Huber K Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625 [TBL] [Abstract][Full Text] [Related]
6. Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999. McCullough PA; Marks KR J Thromb Thrombolysis; 1999 Jun; 7(3):233-9. PubMed ID: 10373716 [No Abstract] [Full Text] [Related]
7. Contemporary use of antiplatelet therapies in percutaneous coronary interventions. Saw J; Moliterno DJ Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902 [No Abstract] [Full Text] [Related]
8. [Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)]. Gratsianskiĭ NA Kardiologiia; 2003; 43(5):71-3. PubMed ID: 12942928 [No Abstract] [Full Text] [Related]
9. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Denardo SJ; Davis KE; Tcheng JE Am Heart J; 2005 Jan; 149(1):138-44. PubMed ID: 15660045 [TBL] [Abstract][Full Text] [Related]
10. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. Gregorini L; Marco J; Fajadet J; Bernies M; Cassagneau B; Brunel P; Bossi IM; Mannucci PM J Am Coll Cardiol; 1997 Jan; 29(1):13-20. PubMed ID: 8996289 [TBL] [Abstract][Full Text] [Related]
11. [Recommendations for peri-procedural thrombocyte aggregation inhibition]. Sauer H; Leschke M Dtsch Med Wochenschr; 2006 Feb; 131(8):400-2. PubMed ID: 16479474 [No Abstract] [Full Text] [Related]
12. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. Leopold JA; Antman EM Circulation; 2005 Mar; 111(9):1097-9. PubMed ID: 15753225 [No Abstract] [Full Text] [Related]
13. Durability of platelet inhibition by clopidogrel. Gurbel PA; Bliden KP Am J Cardiol; 2003 May; 91(9):1123-5. PubMed ID: 12714161 [No Abstract] [Full Text] [Related]
14. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Matetzky S; Shenkman B; Guetta V; Shechter M; Beinart R; Goldenberg I; Novikov I; Pres H; Savion N; Varon D; Hod H Circulation; 2004 Jun; 109(25):3171-5. PubMed ID: 15184279 [TBL] [Abstract][Full Text] [Related]
16. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352 [TBL] [Abstract][Full Text] [Related]
17. Antiplatelet resistance--fact or myth? Gurbel PA; Tantry US Am Heart Hosp J; 2009; 7(1):50-7. PubMed ID: 19742434 [No Abstract] [Full Text] [Related]
18. Advances in post stenting medication protocol. Morice MC J Invasive Cardiol; 1995; 7 Suppl A():32A-35A. PubMed ID: 10155114 [No Abstract] [Full Text] [Related]
19. Switching thienopyridines: hypothetical versus real risks. Serebruany VL J Am Coll Cardiol; 2008 Feb; 51(7):775; author reply 75-6. PubMed ID: 18279745 [No Abstract] [Full Text] [Related]
20. Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough. Yehudai L; Feit F J Interv Cardiol; 2006 Oct; 19(5):464-9. PubMed ID: 17020572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]